AiCuris at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
AiCuris brings 4 presentations to IDWeek 2026 in Washington. Its program centres on pritelivir for hard-to-treat herpes simplex virus in immunocompromised adults and on an antisense drug for BK virus in kidney transplant recipients. It covers how acid-reducing medicines affect pritelivir levels, and the BK drug's safety in healthy volunteers and coverage of virus strains.
| Organization | IDWeek 2026 Attendance |
|---|---|
AiCuris Wuppertal, Germany | |
German anti-infective drug developer behind letermovir and pritelivir, an antiviral for refractory herpes simplex infections. | Industry Fri Oct 23 8:48am–9:00am Pritelivir for refractory HSV infections in immunocompromised adults Antimicrobials, resistance and stewardshipTransplant and immunocompromised hosts Poster Sat Oct 24 12:15pm–1:30pm AIC468, a Novel Antisense Oligonucleotide in Clinical Development for the Treatment of BKV in Kidney Transplant Recipients: Evidence of Broad BKV Strain Coverage and a Low Probability of Pre‑Existing Drug Resistance Poster Sat Oct 24 12:15pm–1:30pm Impact of Acid-Reducing Agents on the Pharmacokinetics of Pritelivir, a Novel Oral Herpes Simplex Virus (HSV) Helicase-Primase Inhibitor Poster Sat Oct 24 12:15pm–1:30pm Safety and Pharmacokinetics of AIC468, a Novel Antisense Oligonucleotide Targeting BK-Virus Transcripts, Following Multiple Dosing in Healthy Volunteers |
Instantly find 20 buyers from AiCuris
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction